We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications.

Our product candidates

Our lead candidate is VB-111, a gene-based biologic agent for solid tumor indications which we have advanced to programs for ovarian cancer, recurrent glioblastoma, colon cancer and thyroid cancer.

In addition, VBL has developed two innovative programs that are based on our novel biological findings related to an exciting new highly specific protein called MOSPD2. Our finding unrevealed the role of MOSPD2 in controlling directed cell movement of immune and tumor cells. We are developing proprietary monoclonal antibodies targeting MOSPD2 for immune inflammatory diseases as well as bi-specific antibodies for cancer.

VBL has also developed a proprietary platform of investigational orally-available anti-inflammatory small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Extraordinary General Meeting of shareholders of Vascular Biogenics Ltd., or the Company, to be held at 4:00 p.m. (Israel time) on November 24, 2020, at our offices at 8 HaSatat St. Modiin, Israel

VBLT – Notice and Invitation to the Extraordinary shareholders meeting

EGM November 24 2020 – proxy card

OVAL Interim data – KOL Call